Abstract:The immunoglobulin variable region (IgHV) which also be called the idiotype (Id) is the best-characterized tumor antigen expressed in B-cell lymphoma. It can function as a target for T-cell-mediated immune responses. However, the usefulness of this approach is limited because vaccines must be patient-specific. IgHV gene can be divided into seven subfamilies, which share the same gene sequence within their framework regions (FR). Here, we choice some peptides derived from the different gene subfamily FRs, and tried to identify if these peptides were capable of inducing cytotoxic T-lymphocyte (CTL) responses, and if the special CTL had possibility to kill B-cell lymphoma cells that belonging to the same subfamily. Meantime we explore if the limitations could be overcome by using the FR-derived peptides. In our study, we amplified seven respective IgHV gene subfamilies by PCR and directly sequenced for 108 cases of acute lymphoblastic leukemias. Complete VHDJH rearrangements were identified in 71(66%)out of 108 cases with 34 (47.89%) monoallelic rearrangements, 30 (42.25%) biallelic rearrangements and 7 (9.86%) oligoclonal rearrangements. SYFPEITHI and BIMAS software databases were used to predict T-cell epitopes in the seven different IgHV subfamily's FR, and to find that these peptides have the same sequence as their germ line gene. Using an antigen-specific T-cell expansion system in vitro, we stimulated the PBMC from the health HLA-A0201 donor by the IgHV1 peptide(QLVQSGAEV) loading APC every week, and demonstrated that the predicted peptides could generate peptide-specific CTL successfully in healthy donors. The frequency of CD8+ and IgHV1 peptide(QLVQSGAEV)/tetramer+ double positive cells in the gated lymphocyte population was 0.38% before stimulation and increased to 49.38 % after forth stimulation . The cytokine release assay and the cytotoxicity assay indicate that these CTLs are capable of killing the lymphoma cell line belonging to the same family in a peptide-specific, and MHC-restricted way. Furthermore, the CTL stimulated by the IgHV1 peptide cannot kill the target cell pulsing a different subfamily peptide, indicating that the cytotoxicity is family-specific. Using the RT-PCR method, TCRBV expression of the CTLs were analyzed and the PCR products were sequenced directly. We found after four stimulations, the TCRBV expression were skewed in several families, and all the clones were found to have identical nucleotide sequences. In conclusion, our results demonstrate that the family-specific peptides derived from the IgHV FR can successfully lead to the generation of peptide-specific CTLs in vitro. Such defined antigenic epitopes may not only serve as candidates for novel lymphoma immunotherapy strategies, but also may help in discovering the interaction between the B-cell and T-cell clones.

Specific Humoral Immune Response Induced by Peptides of 6B11 Ovarian Cancer Anti-Idiotypic Antibody

Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody

New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen

Humoral Immune Responses Induced By Anti-Idiotypic Antibody Fusion Protein Of 6b11scfv/Hgm-Csf In Balb/C Mice

[In Vivo Study of Antitumor Immune Responses Induced by Anti-Idiotypic Minibody Vaccine of Ovarian Cancer].

Study of Immunization Protocol of Ovarian Carcinoma Associated 6B11 Anti-Idiotypical Minibody

Preparation Of Humanized Ovarian Carcinoma Anti-Idiotypic Minibody

Anti-ovarian Tumor Immune Responses Induced by the Fusion Protein of Anti-Idiotypic Single Chain Antibody-Heat Shock 70 in Vitro

Study of anti-idiotype vaccine against ovarian carcinoma

Construction,expression,and Identification of Ovarian Anti-Idiotypic Single Chain Antibody 6b11scfv and Mouse HSP70 Fusion Protein

Specific Immune Cell Therapy Against Ovarian Cancer in Vivo and in Vitro

In Vitro Study on Cytotoxicity of T Cells Induced by Dendritic Cells Loaded with 6B11 Anti-Idiotypeminibody to Ovarian Cancer Cell Lines

The Construction and Expression of Humanized Anti- Idiotypical Antibody Mimic to Ovarian Carcinoma Antigen

The Anti-Tumor Immune Responses Induced by a Fusion Protein of Ovarian Carcinoma Anti-Idiotypic Antibody 6b11scfv and Murine GM-CSF in BALB/c Mice

Humanization of Ovarian Carcinoma Anti-idiotype Single-chain (V_L-V_H-CH3) Antibody

[Preparation and Characterization of Monoclonal Anti-Anti-idiotypic Antibody (3D12) of Epithelial Ovarian Carcinoma].

Vaccination with Monoclonal Anti-Idiotypic Antibody on Immunocompetent Mice Bearing Human Ovarian Carcinoma

[The Study of Immunotherapy of Ovarian Carcinoma with Anti-Idiotypic Antibody].

[Immuno-Therapeutic Study of Anti-Idiotype Minibody (single Chain Fv-CH3) on Ovarian Carcinoma Bearing Mice].

Construction, Expression, and Function of 6B11scfv–mil-12, a Fusion Protein That Attacks Human Ovarian Carcinoma

Induction Of Potent Anti-B-Cell Lymphoma Ctl Responses By The Same Immunoglobulin Variable Region Subfamily Framework-Derived Peptides.